High out-of-pocket costs reduce participation in cardiac rehabilitation

AlloVir is pon­der­ing its cor­po­rate fu­ture af­ter find­ing out that its lead an­tivi­ral cell ther­a­py can­di­date is like­ly in­ef­fec­tive. The biotech had been test­ing posoleu­cel,

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes